Search for:
Search for:
Healthcare Professionals
Publications
News
EspaƱol
Contact
Magazine
Radio
Donate
Get Educated
What is MS?
A chronic neurological disorder that affects the central nervous system, comprised of the brain...
More Details
Educational Materials
Common Questions
Lending Library
Symptoms
Treatment Options
Additional Resources
Research
MS Awareness Month
Get Help
Health & Wellness Program
Get educational materials and referrals, as well as the opportunity to participate in various...
Learn More
Grants & Programs
Awareness Campaigns
Support Groups
Events
Lending Library
Additional Resources
Get Involved
MS Awareness Month
An annual, nationwide campaign with goals to promote an understanding of MS, and to assist those...
Learn More
Advocacy
Buy from Partners
Volunteer
Businesses
MS Research Trials
Outreach
Awareness Campaigns
Host an Event
Events
Test Flyout
lorem ipsum dolor sit lorem ipsum dolor sit lorem ipsum dolor sit lorem ipsum dolor sit lorem...
Learn More
Events Calendar
Health & Wellness
Fundraisers
Support
Web & Teleconferences
MS Education
Host an Event
About Us
Programs & Grants
More Details
Overview
Press Room
Leadership
Financial Statements
Our Mission
Careers at MS Focus
Affiliations
News & Features
Bengals vs Dolphins
The Miami Dolphins take on the Cincinnati Bengals and a portions of ticket sales will support the programs...
/Events/MSF-Events/2019/Third-Party-Events/Bengals-vs-Dolphins
Cooling Program
The Cooling Program offers a variety of items, free of charge, to help individuals with MS...
/Get-Help/MSF-Programs-Grants/Cooling-Program
Shop
Privacy
Terms of Use
Site Map
FDA approves Dysport for treatment of lower limb spasticity
June 28, 2017
The U.S. Food and Drug Administration has expanded the approved use of Dysport® (abobotulinumtoxinA) for the treatment of spasticity in adults.
In a Phase III study, adult patients treated with Dysport following a stroke or traumatic brain injury showed improvement in muscle tone at the ankle joint, measured by the mean change from baseline on the Modified Ashworth Scale at week four. The duration of response for the majority of patients within the study was between 12-16 weeks. In this study, some patients experienced a longer duration of response.
Dysport comes with a warning that the effects of the botulinum toxin may spread from the area of injection to other areas of the body, causing symptoms similar to those of botulism. Those symptoms include swallowing and breathing difficulties that can be life-threatening. Dysport is not for patients with known hypersensitivity to any botulinum toxin preparation or to any of the components; or in the presence of infection at the proposed injection site(s); or in patients known to be allergic to cow’s milk protein.
Spasticity is a condition in which there is an abnormal increase in muscle tone or stiffness in one or more muscles, which might interfere with movement. Spasticity is usually caused by damage to nerve pathways in the brain or spinal cord that control muscle movement, and two in three patients with MS will develop lower limb spasticity.
Lower limb spasticity commonly involves spasticity in calf muscles, which, during walking, work to raise the heel from the ground. Symptoms of spasticity may include increased muscle tone, rapid muscle contractions, exaggerated deep tendon reflexes, and/or muscle spasms. The degree of spasticity can vary from mild muscle stiffness to severe, painful, and uncontrollable muscle spasms.
MS Focus Lending Library
Books, DVDs, and CDs are available for loan, by mail across the United States.
Learn more
Study uncovers potential risks of common MS treatment
Study finds an increased risk of events such as stroke, migraine, and depression, and abnormalities in the blood with taking beta interferon for MS.
Learn more